Patents by Inventor Yannick Rose

Yannick Rose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF
    Publication number: 20260137697
    Abstract: Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are of Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein R1, R2, X1, X2, X3, and X4 are as defined herein.
    Type: Application
    Filed: October 12, 2023
    Publication date: May 21, 2026
    Inventors: Pierre Louis BEAULIEU, Eric BEAULIEU, Emeline BENOIT, Jonne TAN, Yannick ROSE, Michael DORE, Mukund GHAVRE, Doris SCHUETZ
  • Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease
    Patent number: 12479842
    Abstract: Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are of Formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, X1, X2, X3 and X4 are as defined herein.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: November 25, 2025
    Assignee: Universite de Montreal
    Inventors: Pierre Louis Beaulieu, Eric Beaulieu, Joanne Tan, Yannick Rose, Michael Dore, Doris Schuetz, Mukund Ghavre, Jacques Banville
  • Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease
    Patent number: 12060353
    Abstract: Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: August 13, 2024
    Assignee: Université de Montréal
    Inventors: Pierre Louis Beaulieu, Eric Beaulieu, Sasmita Tripathy, Emeline Benoit, Joanne Tan, Hugo Lavoie, Yannick Rose, Michael Dore, Doris Schuetz, Mukund Ghavre, Jacques Banville
  • PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF
    Publication number: 20240239801
    Abstract: Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation.
    Type: Application
    Filed: April 19, 2022
    Publication date: July 18, 2024
    Applicant: Université de Montréal
    Inventors: Pierre Louis BEAULIEU, Eric BEAULIEU, Sasmita TRIPATHY, Yannick ROSE, Michael DORE
  • PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE
    Publication number: 20240217971
    Abstract: Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are of Formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, X1, X2, X3 and X4 are as defined herein.
    Type: Application
    Filed: April 19, 2022
    Publication date: July 4, 2024
    Inventors: Pierre Louis BEAULIEU, Eric BEAULIEU, Sasmita TRIPATHY, Emeline BENOIT, Joanne TAN, Hugo LAVOIE, Yannick ROSE, Michael DORE, Doris SCHUETZ, Mukund GHAVRE, Jacques BANVILLE
  • PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE
    Publication number: 20240140945
    Abstract: Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation.
    Type: Application
    Filed: November 2, 2023
    Publication date: May 2, 2024
    Inventors: Pierre Louis BEAULIEU, Eric BEAULIEU, Sasmita TRIPATHY, Emeline BENOIT, Joanne TAN, Hugo LAVOIE, Yannick ROSE, Michael DORE, Doris SCHUETZ, Mukund GHAVRE, Jacques BANVILLE
  • NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS
    Publication number: 20200385369
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, and its use in therapy.
    Type: Application
    Filed: January 8, 2020
    Publication date: December 10, 2020
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Heterocyclic Tec-Family Kinase Inhibitors
    Publication number: 20200247808
    Abstract: Compounds having the Formula (I), and enantiomers, diastereomers, pharmaceutically acceptable salts, solvates and solvates of salts thereof, (Formula I)) are useful as kinase inhibitors or modulators, including BTK modulation or inhibition, wherein X1, X2, m, m?, E and R1 are as defined herein.
    Type: Application
    Filed: September 9, 2016
    Publication date: August 6, 2020
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Benzimidazoles derivatives as Tec kinases family inhibitors
    Patent number: 10562893
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof and its use in therapy.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: February 18, 2020
    Assignee: GB005, INC.
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS
    Publication number: 20180319781
    Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof and its use in therapy.
    Type: Application
    Filed: September 22, 2016
    Publication date: November 8, 2018
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Inhibitors of the TEC Kinase Enzyme Family
    Publication number: 20180179210
    Abstract: The present invention relates to a novel family of kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly BTK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 28, 2018
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Protein kinase inhibitors
    Patent number: 9822120
    Abstract: The present invention relates to a novel family of protein kinase inhibitors of Formula I: as well as to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: November 21, 2017
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Selective inhibitors of Tec and Src protein kinase families
    Patent number: 9796716
    Abstract: The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: October 24, 2017
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose, James B. Jaquith
  • Protein kinase inhibitors
    Patent number: 9795608
    Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: October 24, 2017
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose
  • Protein Kinase Inhibitors
    Publication number: 20170158697
    Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated.
    Type: Application
    Filed: November 26, 2014
    Publication date: June 8, 2017
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Protein kinase inhibitors
    Patent number: 9624239
    Abstract: The present invention relates to a novel family of inhibitors of protein kinases of Formula (1) wherein X is selected from CH2, O, S(0)n, or NR6; and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src, Btk and Lck protein kinase families.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: April 18, 2017
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
  • PROTEIN KINASE INHIBITORS
    Publication number: 20160375027
    Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicant: PHARMASCIENCE, INC.
    Inventors: Alain LAURENT, Yannick ROSE
  • Protein Kinase Inhibitors
    Publication number: 20160289236
    Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, their intermediates, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune, or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.
    Type: Application
    Filed: November 19, 2014
    Publication date: October 6, 2016
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Protein Kinase Inhibitors
    Publication number: 20160280711
    Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.
    Type: Application
    Filed: November 20, 2014
    Publication date: September 29, 2016
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Protein kinase inhibitors
    Patent number: 9447102
    Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: September 20, 2016
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose